| Idioma original | Anglès |
|---|---|
| Pàgines (de-a) | 1043-1043 |
| Nombre de pàgines | 1 |
| Revista | Journal of Allergy and Clinical Immunology: In Practice |
| Volum | 9 |
| Número | 2 |
| DOIs | |
| Estat de la publicació | Publicada - de febr. 2021 |
SDG de les Nacions Unides
Aquest resultat contribueix als següents objectius de desenvolupament sostenible.
Accés al document
- 10.1016/j.jaip.2020.11.014Llicència: No especificat
Altres arxius i enllaços
Com citar-ho
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 2, 02.2021, pàg. 1043-1043.
Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts
TY - JOUR
T1 - Reply to “Managing T2-high severe asthma in HIV-infected patients”
AU - Curto, Elena
AU - Torrego, Alfons
AU - Garin, Noe
AU - Crespo-Lessmann, Astrid
AU - Plaza, Vicente
N1 - Funding Information: No funding was received for this work. Conflicts of interest: E. Curto has received funding as speaker, and travel/attend training activities from ALK, Menarini, Teva, AstraZeneca, Chiesi, Boehringer, and Novartis. A. Torrego declares no relevant conflicts of interest. N. Garin received honoraria for speaking at sponsored meetings from AZ and GSK. A. Crespo-Lessmann in the last 3 years has received honoraria for speaking at sponsored meetings from AstraZeneca, Chiesi, Esteve Laboratories, Faes Farma, Ferrer, GlaxoSmithKline, Novartis, Teva, and Zambon; received help assistance to meeting travel from Bial and Novartis; acts as a consultant for AstraZeneca, Boehringer, GlaxoSmithKline, and Novartis; and received funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as AstraZeneca and GSK. V. Plaza in the last 3 years has received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, and Novartis; received financial support to travel to meetings organized by Chiesi and Novartis; is a consultant for ALK, AstraZeneca, Boehringer, MundiPharma, and Sanofi; and received funding/grant support for research projects from a variety of governmental agencies and not-for-profit foundations, as well as from AstraZeneca, Chiesi, and Menarini.
PY - 2021/2
Y1 - 2021/2
UR - https://www.scopus.com/pages/publications/85100058333
U2 - 10.1016/j.jaip.2020.11.014
DO - 10.1016/j.jaip.2020.11.014
M3 - Article
C2 - 33551032
AN - SCOPUS:85100058333
SN - 2213-2198
VL - 9
SP - 1043
EP - 1043
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 2
ER -